BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1083 related articles for article (PubMed ID: 37141907)

  • 81. Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine : A Case-Control Study.
    Lai FTT; Li X; Peng K; Huang L; Ip P; Tong X; Chui CSL; Wan EYF; Wong CKH; Chan EWY; Siu DCW; Wong ICK
    Ann Intern Med; 2022 Mar; 175(3):362-370. PubMed ID: 35073155
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Dynamic of anti-spike receptor binding domain (RBD) levels and short-term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers.
    Kitro A; Sirikul W; Thongkum W; Soponpong S; Yasamut U; Kiratipaisarl W; Kosai A; Kasinrerk W; Tayapiwatana C; Srithanaviboonchai K
    Vaccine; 2022 May; 40(21):2915-2924. PubMed ID: 35430106
    [TBL] [Abstract][Full Text] [Related]  

  • 83. SARS-CoV-2 infection following booster vaccination: Illness and symptom profile in a prospective, observational community-based case-control study.
    Antonelli M; Penfold RS; Canas LDS; Sudre C; Rjoob K; Murray B; Molteni E; Kerfoot E; Cheetham N; Pujol JC; Polidori L; May A; Wolf J; Modat M; Spector T; Hammers A; Ourselin S; Steves C
    J Infect; 2023 Dec; 87(6):506-515. PubMed ID: 37777159
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Waning effectiveness of BNT162b2 and ChAdOx1 covid-19 vaccines over six months since second dose: OpenSAFELY cohort study using linked electronic health records.
    Horne EMF; Hulme WJ; Keogh RH; Palmer TM; Williamson EJ; Parker EPK; Green A; Walker V; Walker AJ; Curtis H; Fisher L; MacKenna B; Croker R; Hopcroft L; Park RY; Massey J; Morley J; Mehrkar A; Bacon S; Evans D; Inglesby P; Morton CE; Hickman G; Davy S; Ward T; Dillingham I; Goldacre B; Hernán MA; Sterne JAC
    BMJ; 2022 Jul; 378():e071249. PubMed ID: 35858698
    [TBL] [Abstract][Full Text] [Related]  

  • 85. The Vaccine Efficacy Against the SARS-CoV-2 Omicron: A Systemic Review and Meta-Analysis.
    Zou Y; Huang D; Jiang Q; Guo Y; Chen C
    Front Public Health; 2022; 10():940956. PubMed ID: 35910897
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study.
    Nyberg T; Ferguson NM; Nash SG; Webster HH; Flaxman S; Andrews N; Hinsley W; Bernal JL; Kall M; Bhatt S; Blomquist P; Zaidi A; Volz E; Aziz NA; Harman K; Funk S; Abbott S; ; Hope R; Charlett A; Chand M; Ghani AC; Seaman SR; Dabrera G; De Angelis D; Presanis AM; Thelwall S
    Lancet; 2022 Apr; 399(10332):1303-1312. PubMed ID: 35305296
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study.
    Suah JL; Husin M; Tok PSK; Tng BH; Thevananthan T; Low EV; Appannan MR; Muhamad Zin F; Mohd Zin S; Yahaya H; Peariasamy KM; Sivasampu S
    Int J Infect Dis; 2022 Jun; 119():69-76. PubMed ID: 35331933
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Three-dose vaccination-induced immune responses protect against SARS-CoV-2 Omicron BA.2: a population-based study in Hong Kong.
    Zhou R; Liu N; Li X; Peng Q; Yiu CK; Huang H; Yang D; Du Z; Kwok HY; Au KK; Cai JP; Fan-Ngai Hung I; Kai-Wang To K; Xu X; Yuen KY; Chen Z
    Lancet Reg Health West Pac; 2023 Mar; 32():100660. PubMed ID: 36591327
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study.
    Chemaitelly H; Ayoub HH; AlMukdad S; Coyle P; Tang P; Yassine HM; Al-Khatib HA; Smatti MK; Hasan MR; Al-Kanaani Z; Al-Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul-Rahim HF; Nasrallah GK; Al-Kuwari MG; Butt AA; Al-Romaihi HE; Al-Thani MH; Al-Khal A; Bertollini R; Abu-Raddad LJ
    Lancet Microbe; 2022 Dec; 3(12):e944-e955. PubMed ID: 36375482
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Safety and effectiveness of vaccines against COVID-19 in children aged 5-11 years: a systematic review and meta-analysis.
    Piechotta V; Siemens W; Thielemann I; Toews M; Koch J; Vygen-Bonnet S; Kothari K; Grummich K; Braun C; Kapp P; Labonté V; Wichmann O; Meerpohl JJ; Harder T
    Lancet Child Adolesc Health; 2023 Jun; 7(6):379-391. PubMed ID: 37084750
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Effectiveness of mRNA COVID-19 Vaccine Boosters Against Infection, Hospitalization, and Death: A Target Trial Emulation in the Omicron (B.1.1.529) Variant Era.
    Ioannou GN; Bohnert ASB; O'Hare AM; Boyko EJ; Maciejewski ML; Smith VA; Bowling CB; Viglianti E; Iwashyna TJ; Hynes DM; Berry K;
    Ann Intern Med; 2022 Dec; 175(12):1693-1706. PubMed ID: 36215715
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales.
    Agrawal U; Bedston S; McCowan C; Oke J; Patterson L; Robertson C; Akbari A; Azcoaga-Lorenzo A; Bradley DT; Fagbamigbe AF; Grange Z; Hall ECR; Joy M; Katikireddi SV; Kerr S; Ritchie L; Murphy S; Owen RK; Rudan I; Shah SA; Simpson CR; Torabi F; Tsang RSM; de Lusignan S; Lyons RA; O'Reilly D; Sheikh A
    Lancet; 2022 Oct; 400(10360):1305-1320. PubMed ID: 36244382
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Effectiveness of the BNT162b2 and the CoronaVac vaccines and boosters in healthcare workers.
    Çulpan HC; Aydın SN; Uygur A; Sayılı U; Şeker E; Balkan ILİ; Karaali R; Budak B; Keskindemirci Y; Saltoğlu N; Can G
    Hum Vaccin Immunother; 2023 Dec; 19(3):2275445. PubMed ID: 37964650
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Association of COVID-19 vaccination with duration of hospitalization in older adults in Hong Kong.
    Chen D; Cowling BJ; Ainslie KEC; Lin Y; Wong JY; Lau EHY; Wu P; Nealon J
    Vaccine; 2024 Apr; 42(9):2385-2393. PubMed ID: 38448323
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study.
    Fabiani M; Puopolo M; Morciano C; Spuri M; Spila Alegiani S; Filia A; D'Ancona F; Del Manso M; Riccardo F; Tallon M; Proietti V; Sacco C; Massari M; Da Cas R; Mateo-Urdiales A; Siddu A; Battilomo S; Bella A; Palamara AT; Popoli P; Brusaferro S; Rezza G; Menniti Ippolito F; Pezzotti P;
    BMJ; 2022 Feb; 376():e069052. PubMed ID: 35144968
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Effectiveness of BNT162b2 and CoronaVac vaccines against omicron in children aged 5 to 11 years.
    Oliveira EA; Oliveira MCL; Silva ACSE; Colosimo EA; Mak RH; Vasconcelos MA; Silva LR; Martelli DB; Pinhati CC; Martelli-Júnior H
    World J Pediatr; 2023 Oct; 19(10):949-960. PubMed ID: 36914907
    [TBL] [Abstract][Full Text] [Related]  

  • 97. COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study.
    Sing CW; Tang CTL; Chui CSL; Fan M; Lai FTT; Li X; Wan EYF; Wong CKH; Chan EWY; Hung IFN; Leung AY; Cheung CL; Wong ICK
    Am J Hematol; 2022 Apr; 97(4):470-480. PubMed ID: 35080247
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial.
    Zhang Y; Ma X; Yan G; Wu Y; Chen Y; Zhou Z; Wan N; Su W; Liu FW; Dai MX; Yang M; Li C; Yu X; Zhang L; Wang Z; Zhou TC; You D; Wei J; Zhang Z;
    EClinicalMedicine; 2022 Dec; 54():101680. PubMed ID: 36188435
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Initial protection against SARS-CoV-2 omicron lineage infection in children and adolescents by BNT162b2 in Israel: an observational study.
    Amir O; Goldberg Y; Mandel M; Bar-On YM; Bodenheimer O; Freedman L; Ash N; Alroy-Preis S; Huppert A; Milo R
    Lancet Infect Dis; 2023 Jan; 23(1):67-73. PubMed ID: 36096146
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study.
    Tartof SY; Slezak JM; Fischer H; Hong V; Ackerson BK; Ranasinghe ON; Frankland TB; Ogun OA; Zamparo JM; Gray S; Valluri SR; Pan K; Angulo FJ; Jodar L; McLaughlin JM
    Lancet; 2021 Oct; 398(10309):1407-1416. PubMed ID: 34619098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 55.